Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Salt Lake City, Utah 84108


The investigators hypothesize that the administration of two widely available, naturally occurring dietary supplements, 5 hydroxytryptophan and creatine monohydrate, will reduce the severity of depression in individuals exposed to chronic hypoxia by living at altitude. The purpose of this study is to determine if 8 weeks of dietary augmentation with oral 5 g creatine daily and 100 mg 5-HTP twice daily reduces hypoxia-related depressive symptoms measured by the 17-item Hamilton Depression Rating Scale (HAM-D) in women with SSRI or SNRI-resistant depression.

Study summary:

Serotonin and creatine are processed separately in the brain, and deficits in these brain biochemicals lead to distinct clinical problems. Therefore, investigators believe that treatment with a combination therapy, which could correct both deficits, would have a synergistic effect in the treatment of hypoxia-related depression and possibly other forms of treatment-resistant depression. Thus, investigators propose to investigate antidepressant efficacy of dietary 5-hydroxytryptophan (5-HTP) and creatine, as a means to restore the brain neurotransmitter and metabolic imbalances linked to chronic hypoxia caused by high altitude residence.


Inclusion Criteria: - Female gender, ages 18-64 years inclusive - Current diagnosis of Major Depressive Disorder identified by the SCID-5-CT - Current HAM-D17 score of > 15 - Adequate adherence to any FDA approved SSRI or SNRI for at least 8 weeks Exclusion Criteria: - Diagnosis of bipolar disorder, schizophrenia, or schizoaffective disorder, identified by the SCID-5-CT - History of or current diagnosis of renal disease, such as chronic renal failure, acute renal failure or end stage renal disease - Diabetes type I or II - Colitis or diverticulitis - History of pulmonary disease - History of fibromyalgia, lupus, eosinophilia myalgia syndrome, dermatomyositis, polymyositis, rheumatoid arthritis, psoriatic arthritis, mixed connective tissue disease, ankylosing spondylitis, or other related rheumatological condition - Seizure disorder - Current serious suicide risk identified by the Columbia Severity Suicide Rating Scale - Current treatment with an antipsychotic, mood stabilizer, or non-SSRI antidepressant - Positive pregnancy test - Previous diagnosis of serotonin syndrome - Use of any excluded drugs or medications including serotonergic drugs or medications



Primary Contact:

Study Director
Perry F. Renshaw, MD, PhD, MBA
University of Utah

Backup Contact:


Location Contact:

Salt Lake City, Utah 84108
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.